132 related articles for article (PubMed ID: 34981886)
1. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review.
Frezoulis P; Harper A
Vet Comp Oncol; 2022 Jun; 20(2):362-371. PubMed ID: 34981886
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
London C; Mathie T; Stingle N; Clifford C; Haney S; Klein MK; Beaver L; Vickery K; Vail DM; Hershey B; Ettinger S; Vaughan A; Alvarez F; Hillman L; Kiselow M; Thamm D; Higginbotham ML; Gauthier M; Krick E; Phillips B; Ladue T; Jones P; Bryan J; Gill V; Novasad A; Fulton L; Carreras J; McNeill C; Henry C; Gillings S
Vet Comp Oncol; 2012 Sep; 10(3):194-205. PubMed ID: 22236194
[TBL] [Abstract][Full Text] [Related]
3. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
Kim C; Matsuyama A; Mutsaers AJ; Woods JP
Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
[TBL] [Abstract][Full Text] [Related]
4. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J
Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.
Laver T; London CA; Vail DM; Biller BJ; Coy J; Thamm DH
Vet Comp Oncol; 2018 Mar; 16(1):E23-E29. PubMed ID: 28621057
[TBL] [Abstract][Full Text] [Related]
6. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
7. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
Harper A; Blackwood L
J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
[TBL] [Abstract][Full Text] [Related]
9. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
London CA; Gardner HL; Mathie T; Stingle N; Portela R; Pennell ML; Clifford CA; Rosenberg MP; Vail DM; Williams LE; Cronin KL; Wilson-Robles H; Borgatti A; Henry CJ; Bailey DB; Locke J; Northrup NC; Crawford-Jakubiak M; Gill VL; Klein MK; Ruslander DM; Thamm DH; Phillips B; Post G
PLoS One; 2015; 10(4):e0124889. PubMed ID: 25923466
[TBL] [Abstract][Full Text] [Related]
10. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
Musser ML; Johannes CM
BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
14. Investigation of thyroid function in dogs treated with the tyrosine kinase inhibitor toceranib.
Harper A; Blackwood L; Mason S
Vet Comp Oncol; 2020 Sep; 18(3):433-437. PubMed ID: 31498949
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
Heaton CM; Fernandes AFA; Jark PC; Pan X
J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135
[TBL] [Abstract][Full Text] [Related]
16. Palmar-plantar erythrodysesthesia syndrome resulting from toceranib phosphate in a dog with apocrine gland anal sac adenocarcinoma: a case report.
Kim E; Kim SS; Ryu MO
J Vet Sci; 2023 Nov; 24(6):e76. PubMed ID: 37904638
[TBL] [Abstract][Full Text] [Related]
17. Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017).
Elliott JW
J Am Vet Med Assoc; 2019 Apr; 254(8):960-966. PubMed ID: 30938616
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia.
Alonso-Miguel D; García-San José P; González Sanz S; Clarés Moral I; Pérez-Alenza MD
N Z Vet J; 2021 Jul; 69(4):234-239. PubMed ID: 33944682
[TBL] [Abstract][Full Text] [Related]
19. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
[TBL] [Abstract][Full Text] [Related]
20. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
Remerowski SM; Herrera CL; Donnelly LL
BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
